mTOR signaling in polycystic kidney disease
- PMID: 21775207
- DOI: 10.1016/j.molmed.2011.06.003
mTOR signaling in polycystic kidney disease
Abstract
Polycystic kidney diseases (PKDs) comprise a large group of genetic disorders characterized by formation of cysts in the kidneys and other organs, ultimately leading to end-stage renal disease. Although PKDs can be caused by mutations in different genes, they converge on a set of common molecular mechanisms involved in cystogenesis and ciliary dysfunction, and can be qualified as ciliopathies. Recent advances in understanding the mechanisms regulating disease progression have led to the development of new therapies that are being tested in both preclinical and clinical trials. In this article, we briefly review a network of molecular pathways of cystogenesis that are regulated by ciliary functions. We discuss the mTOR pathway in depth, highlighting recent progress in understanding its role in PKD and the current results of clinical trials.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
[Recent advances in molecular pathogenesis and treatment of polycystic kidney disease].Rev Med Chir Soc Med Nat Iasi. 2008 Jan-Mar;112(1):11-20. Rev Med Chir Soc Med Nat Iasi. 2008. PMID: 18677899 Review. Romanian.
-
Therapeutic advances in the treatment of polycystic kidney disease.Nephron Clin Pract. 2014;128(3-4):297-302. doi: 10.1159/000368244. Epub 2015 Jan 6. Nephron Clin Pract. 2014. PMID: 25573484 Review.
-
Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.Nephrol Dial Transplant. 2011 Jan;26(1):92-100. doi: 10.1093/ndt/gfq384. Epub 2010 Jul 7. Nephrol Dial Transplant. 2011. PMID: 20615907
-
Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.Am J Physiol Renal Physiol. 2011 May;300(5):F1193-202. doi: 10.1152/ajprenal.00419.2010. Epub 2011 Feb 23. Am J Physiol Renal Physiol. 2011. PMID: 21345977
-
Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment.Nephrol Dial Transplant. 2010 Dec;25(12):3809-12. doi: 10.1093/ndt/gfq527. Epub 2010 Aug 26. Nephrol Dial Transplant. 2010. PMID: 20798121 No abstract available.
Cited by
-
Evidence that TMEM67 causes polycystic kidney disease through activation of JNK/ERK-dependent pathways.Cell Biol Int. 2013 Jul;37(7):694-702. doi: 10.1002/cbin.10081. Epub 2013 Apr 16. Cell Biol Int. 2013. PMID: 23456819 Free PMC article.
-
Primary cilia: Versatile regulator in cartilage development.Cell Prolif. 2020 Mar;53(3):e12765. doi: 10.1111/cpr.12765. Epub 2020 Feb 8. Cell Prolif. 2020. PMID: 32034931 Free PMC article. Review.
-
Bicaudal C mutation causes myc and TOR pathway up-regulation and polycystic kidney disease-like phenotypes in Drosophila.PLoS Genet. 2017 Apr 13;13(4):e1006694. doi: 10.1371/journal.pgen.1006694. eCollection 2017 Apr. PLoS Genet. 2017. PMID: 28406902 Free PMC article.
-
Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade.Am J Physiol Renal Physiol. 2018 Feb 1;314(2):F210-F218. doi: 10.1152/ajprenal.00389.2017. Epub 2017 Oct 11. Am J Physiol Renal Physiol. 2018. PMID: 29021226 Free PMC article.
-
Reciprocal Regulation between Primary Cilia and mTORC1.Genes (Basel). 2020 Jun 26;11(6):711. doi: 10.3390/genes11060711. Genes (Basel). 2020. PMID: 32604881 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous